1
|
|
2
|
Chang MG, Zhang Y, Chang CY, Xu L, Emokpae R, Tung L, Marbán E, Abraham MR. Spiral waves and reentry dynamics in an in vitro model of the healed infarct border zone. Circ Res 2009; 105:1062-71. [PMID: 19815825 DOI: 10.1161/circresaha.108.176248] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
RATIONALE Reentry underlies most ventricular tachycardias (VTs) seen postmyocardial infarction (MI). Mapping studies reveal that the majority of VTs late post-MI arise from the infarct border zone (IBZ). OBJECTIVE To investigate reentry dynamics and the role of individual ion channels on reentry in in vitro models of the "healed" IBZ. METHODS AND RESULTS We designed in vitro models of the healed IBZ by coculturing skeletal myotubes with neonatal rat ventricular myocytes and performed optical mapping at high temporal and spatial resolution. In culture, neonatal rat ventricular myocytes mature to form striated myocytes and electrically uncoupled skeletal myotubes simulate fibrosis seen in the healed IBZ. High resolution mapping revealed that skeletal myotubes produced localized slowing of conduction velocity (CV), increased dispersion of CV and directional-dependence of activation delay without affecting myocyte excitability. Reentry was easily induced by rapid pacing in cocultures; treatment with lidocaine, a Na(+) channel blocker, significantly decreased reentry rate and CV, increased reentry path length and terminated 30% of reentrant arrhythmias (n=18). In contrast, nitrendipine, an L-type Ca(2+) channel blocker terminated 100% of reentry episodes while increasing reentry cycle length and path length and decreasing reentry CV (n=16). K(+) channel blockers increased reentry action potential duration but infrequently terminated reentry (n=12). CONCLUSIONS Cocultures reproduce several architectural and electrophysiological features of the healed IBZ. Reentry termination by L-type Ca(2+) channel, but not Na(+) channel, blockers suggests a greater Ca(2+)-dependence of propagation. These results may help explain the low efficacy of pure Na(+) channel blockers in preventing and terminating clinical VTs late after MI.
Collapse
Affiliation(s)
- Marvin G Chang
- Department of Cardiology, Johns Hopkins Hospital, Baltimore, MD 21205, USA
| | | | | | | | | | | | | | | |
Collapse
|
3
|
KOWEY PETERR, MARINCHAK ROGERA, RIALS SETHJ. The Cardiac Arrhythmia Suppression Trial: How Has it Impacted on Contemporary Arrhythmia Management? J Cardiovasc Electrophysiol 2008. [DOI: 10.1111/j.1540-8167.1990.tb01078.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
4
|
Sassi R, Cerutti S, Hnatkova K, Malik M, Signorini MG. HRV Scaling Exponent Identifies Postinfarction Patients Who Might Benefit From Prophylactic Treatment With Amiodarone. IEEE Trans Biomed Eng 2006; 53:103-10. [PMID: 16402609 DOI: 10.1109/tbme.2005.859806] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Analysing the Holter recordings collected at baseline during the European Myocardial Infarction Amiodarone Trial (EMIAT), we evaluate the possibility of using alpha, the slope of the power spectrum of heart rate variability signals (HRV) in the vicinity of f = 0, for postinfarction risk stratification. We found no relevant difference in the values of alpha for the placebo population. On the contrary, in the amiodarone arm, the distinction in the survival rates of those with high or low alpha-values was highly significant. Moreover, high risk patients with respect to alpha (higher values) did not seem to benefit from amiodarone. The results suggest that alpha might convey physiologic information that is different than what is expressed by other HRV characteristics, such as the triangular index. When combining high risk patients in term of triangular index (<20) and low risk patients with respect to alpha (<median), the difference in survival on placebo and amiodarone became very substantial (24.2% mortality on placebo, 8.7% on amiodarone, p = 0.017). This might offer a possibility of selecting patients likely to benefit from a prophylactic antiarrhythmic treatment after acute myocardial infarction.
Collapse
Affiliation(s)
- Roberto Sassi
- Dipartimento di Bioingegneria, Politecnico di Milano, Italy.
| | | | | | | | | |
Collapse
|
5
|
Kodama I, Ogawa S, Inoue H, Kasanuki H, Kato T, Mitamura H, Hiraoka M, Sugimoto T. Profiles of aprindine, cibenzoline, pilsicainide and pirmenol in the framework of the Sicilian Gambit. The Guideline Committee for Clinical Use of Antiarrhythmic Drugs in Japan (Working Group of Arrhythmias of the Japanese Society of Electrocardiology). JAPANESE CIRCULATION JOURNAL 1999; 63:1-12. [PMID: 10084381 DOI: 10.1253/jcj.63.1] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The Vaughan Williams classification has been used widely by clinicians, cardiologists and researchers engaged in antiarrhythmic drug development and testing in many countries throughout the world since its initial proposal in the early 1970s. However, a major criticism of the Vaughan Williams system arose from the extent to which the categorization of drugs into classes I-IV led to oversimplified views of both shared and divergent actions. The Sicilian Gambit proposed a two-dimensional tabular framework for display of drug actions to solve these problems. From April to December 1996, members of the Guideline Committee met to discuss pharmacologic profiles of 4 antiarrhythmic drugs (aprindine, cibenzoline, pilsicainide, and pirmenol) that were not included in the original spreadsheet but are used widely in clinical practice in Japan. The discussion aimed to fit the drug profiles into the Gambit framework based on all the important literature published to date regarding the actions of the 4 drugs. This report is a summary of that deliberation.
Collapse
Affiliation(s)
- I Kodama
- Research Institute of Environmental Medicine, Nagoya University, Japan
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Abstract
Sudden cardiac death (SCD) remains a significant medical problem in the United States. The incidence of SCD increases with advancing age because cardiovascular disease is more prevalent in the elderly. Management of ventricular arrhythmias in the elderly patient is especially challenging because of increased risk of interventional and pharmacologic therapies, altered pharmacokinetics of drugs, and sometimes unclear long-term benefits.
Collapse
Affiliation(s)
- D D Tresch
- Division of Cardiology, Medical College of Wisconsin, Milwaukee, USA
| | | |
Collapse
|
7
|
Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349:667-74. [PMID: 9078197 DOI: 10.1016/s0140-6736(96)09145-3] [Citation(s) in RCA: 806] [Impact Index Per Article: 29.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND Ventricular arrhythmias are a major cause of death after myocardial infarction, especially in patients with poor left-ventricular function. Previous attempts to identify and suppress arrhythmias with various antiarrhythmic drugs failed to reduce or actually increase mortality. Amiodarone is a powerful antiarrhythmic drug with several potentially beneficial actions, and has shown benefit in several small-scale studies. We postulated that this drug might reduce mortality in patients at high risk of death after myocardial infarction because of impaired ventricular function, irrespective of whether they had ventricular arrhythmias. METHODS The European Myocardial Infarct Amiodarone Trial (EMIAT) was a randomised double-blind placebo-controlled trial to assess whether amiodarone reduced all-cause mortality (primary endpoint) and cardiac mortality and arrhythmic death (secondary endpoints) in survivors of myocardial infarction with a left-ventricular ejection fraction (LVEF) of 40% or less. Intention-to-treat and on-treatment analyses were done. FINDINGS EMIAT enrolled 1486 patients (743 in the amiodarone group, 743 in the placebo group). Median follow-up was 21 months. All-cause mortality (103 deaths in the amiodarone group, 102 in the placebo group) and cardiac mortality did not differ between the two groups. However, in the amiodarone group, there was a 35% risk reduction (95% CI 0-58, p = 0.05) in arrhythmic deaths. INTERPRETATION Our findings do not support the systematic prophylactic use of amiodarone in all patients with depressed left-ventricular function after myocardial infarction. However, the lack of proarrhythmia and the reduction in arrhythmic death support the use of amiodarone in patients for whom antiarrhythmic therapy is indicated.
Collapse
Affiliation(s)
- D G Julian
- St George's Hospital Medical School, London, UK
| | | | | | | | | | | | | |
Collapse
|
8
|
Brembilla-Perrot B, Jacquemin L, Terrier de la Chaise A, Beurrier D. Programmed ventricular stimulation after myocardial infarction does not help reduce the risk of ventricular events. Cardiovasc Drugs Ther 1996; 10:549-56. [PMID: 8950069 DOI: 10.1007/bf00050995] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Programmed ventricular stimulation could be a useful technique to detect patients at high risk for ventricular arrhythmias and sudden death after acute myocardial infarction. However, prevention of arrhythmic events using this technique has never been demonstrated. To determine whether prophylactic antiarrhythmic therapy influences prognosis after acute myocardial infarction, 196 patients without spontaneous ventricular tachycardia (VT) but with inducible sustained monomorphic VT were followed for 3 +/- 1 years. Ninety-seven patients were not treated (control group). In 99 patients (study group), the antiarrhythmic therapy was guided by electrophysiologic study: One to four trials using class I, II, and III antiarrhythmic drugs were performed until the VT was not inducible or the induced VT was slower and was associated with hemodynamic stability. An effective antiarrhythmic drug prevented VT induction in 34 patients (34%; group I). Sixty-five patients (group II) still had inducible VT with the antiarrhythmic drug. Group II differed from group I in having a higher incidence of an inferior myocardial infarction location (57% vs. 47%; NS), a lower left ventricular ejection fraction (36.5% vs. 41%; NS), a slower rate of induced VT in the control state (227 vs. 255 beats/min; p < 0.05), and a higher number of drug trials (1.9 vs 1.3; p < 0.001). During the follow-up in the control group and in groups I and II, the incidence of total cardiac events was 25%, 15%, and 16% (NS), respectively, and the incidence of total arrhythmic events (VT, sudden death) was 18.5%, 9%, and 12% (NS). Only the risk of VT was reduced (14%, 0%, and 4%; p < 0.05). In conclusion, guided-antiarrhythmic therapy, including class III agents after acute myocardial infarction, was successful in only 34% of patients, and the incidence of arrhythmic events was not significantly decreased. Therefore, programmed ventricular stimulation does not help in managing patients at risk of ventricular arrhythmia after myocardial infarction but could help indicate the need for nonmedical treatment, such as device therapy.
Collapse
|
9
|
Kamiyama T, Tanonaka K, Hayashi J, Takeo S. Effects of aprindine on ischemia/reperfusion-induced cardiac contractile dysfunction of perfused rat heart. JAPANESE JOURNAL OF PHARMACOLOGY 1996; 70:227-34. [PMID: 8935716 DOI: 10.1254/jjp.70.227] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The present study was undertaken to determine whether aprindine, a class Ib antiarrythymic agent, exerts beneficial effects on ischemia/reperfusion-induced cardiac contractile dysfunction and metabolic derangement. Isolated rat hearts were subjected to 35-min global ischemia, followed by 60-min reperfusion, and functional and metabolic alterations of the heart were determined with or without aprindine-treatment. Ischemia induced a cessation of left ventricular developed pressure (LVDP), a rise in left ventricular end-diastolic pressure (LVEDP), and an increase in myocardial sodium content and a decrease in myocardial potassium content. When the hearts were reperfused, little recovery of LVDP and sustained rise in LVEDP and perfusion pressure were observed. Ischemia/reperfusion resulted in a release of ATP metabolites and creatine kinase from perfused hearts, an increase in myocardial sodium and calcium contents, and a decrease in myocardial potassium and magnesium contents. Treatment of the perfused heart with either 10 or 30 microM aprindine for the last 3 min of pre-ischemia improved contractile recovery during reperfusion and suppressed changes in myocardial ion content during ischemia and reperfusion. Treatment with the agent also attenuated the release of ATP metabolites and creatine kinase from the heart. However, treatment with high concentrations of aprindine (70 and 100 microM) improved neither cardiac contractile dysfunction, myocardial ionic disturbance nor the release of ATP metabolites and creatine kinase during reperfusion. Two possible mechanisms for the cardioprotection by the agent have been suggested: suppression of transmembrane flux of substrates and enzymes, and prevention of accumulation of myocardial sodium during ischemia.
Collapse
Affiliation(s)
- T Kamiyama
- Department of Pharmacology, Tokyo University of Pharmacy and Life Science, Japan
| | | | | | | |
Collapse
|
10
|
Statters DJ, Malik M, Redwood S, Hnatkova K, Staunton A, Camm AJ. Use of ventricular premature complexes for risk stratification after acute myocardial infarction in the thrombolytic era. Am J Cardiol 1996; 77:133-8. [PMID: 8546079 DOI: 10.1016/s0002-9149(96)90582-2] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The independent predictive role of ventricular premature complex (VPC) frequency in the stratification of mortality risk after acute myocardial infarction (AMI) was established in the prethrombolytic era by extensive multicenter trials. Thrombolysis has lead to important changes in the natural history of patients after AMI, so that reassessment of established risk factors is now required. The prognostic significance of VPCs was assessed in 680 patients, of whom 379 received early thrombolytic therapy. All patients underwent 24-hour Holter monitoring in a drug-free state between 6 and 10 days after AMI. Patients were followed up for 1 to 8 years. During the first year of follow-up, cardiac death occurred in 33 patients, sudden death in 24, and sustained ventricular tachycardia in 20. Mean VPC frequency was significantly higher in patients who died of cardiac causes, in those who died suddenly, and in those with arrhythmic events during the first year of follow-up. This was also true when patients who did and did not undergo thrombolysis were considered separately. The positive predictive accuracy of VPC frequency in predicting adverse cardiac events was greater in patients who did than did not undergo thrombolysis. At a sensitivity level of 40%, the positive predictive accuracy for cardiac mortality and arrhythmic events for the group with thrombolysis was 19.4% and 25.8%, respectively, compared with 16% and 16% for those without thrombolysis. Moreover, the highest VPC frequency for the dichotomy of patients into high-and low-risk groups was 25 VPCs/hour for patients without thrombolysis. VPC frequency appears to be more highly predictive of prognosis after AMI in patients who have undergone thrombolysis than in those who have not, but the optimal frequency for dichotomy is higher in the former.
Collapse
Affiliation(s)
- D J Statters
- Department of Cardiological Sciences, St. George's Hospital Medical School, London, United Kingdom
| | | | | | | | | | | |
Collapse
|
11
|
Miller SM, Mayer RC. Con: antiarrhythmic drugs should not be used to suppress ventricular ectopy in the perioperative period. J Cardiothorac Vasc Anesth 1994; 8:701-3. [PMID: 7533551 DOI: 10.1016/1053-0770(94)90208-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The alterations in autonomic tone imposed by the conduct of anesthesia and surgery predispose patients to ventricular ectopy. It is important to initially view any ectopy as a warning sign and promptly check the adequacy of ventilation and oxygenation. Most commonly an inadequate depth of anesthesia, surgical manipulation or electrolyte abnormality will be causative. Treatment of this underlying problem will usually suffice to terminate the ectopy. Importantly, many patients have preexisting, chronic, complex ventricular ectopy that gets revealed because of perioperative electrocardiographic monitoring. All available pharmacologic agents have significant adverse side effects. To date, all investigations examining outcome of suppression of ventricular ectopy show that successful suppression of ventricular ectopy was associated with an increased mortality. Although the prognosis for patients is worse when complex ventricular ectopy is associated with cardiac structural abnormalities, the optimal therapeutic approach to such patients remains undefined. Unless new data supporting the use of antiarrhythmic drugs in the perioperative setting become available, the risk to benefit ratio is considered unfavorable.
Collapse
Affiliation(s)
- S M Miller
- Department of Anesthesiology, Lutheran General Hospital, Park Ridge, IL 60068
| | | |
Collapse
|
12
|
Reiffel JA, Correia J. "In the absence of structural heart disease...." What is it, and why does it matter in antiarrhythmic drug therapy? Am Heart J 1994; 128:626-9. [PMID: 8074032 DOI: 10.1016/0002-8703(94)90644-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
13
|
Reiffel JA, Correia J. Structural heart disease: its importance in association with antiarrhythmic drug therapy. Clin Cardiol 1994; 17:II3-6. [PMID: 7882611 DOI: 10.1002/clc.4960171404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
The presence or absence of structural heart disease is an important factor to consider prior to initiating antiarrhythmic drug therapy with a class I or class III antiarrhythmic agent. An appropriate screen for structural heart disease and other associated proarrhythmic risk factors should include a complete history, physical examination, electrocardiogram (ECG), and echocardiogram in all patients; exercise test and Holter monitoring in many/most selected patients; and a signal-averaged ECG, chest x-ray, and invasive procedures only in selected/occasional patients. Whether and when to obtain the tests that are not indicated for all patients must be determined by each individual physician's practice strategy and philosophy, while keeping in mind the likelihood of finding an abnormality in a particular patient, the arrhythmia being treated, the nature of the drug to be used, and cost-effectiveness issues. Given the low incidence of proarrhythmia under most circumstances, screening for clinically unrecognized structural heart disease may appear difficult to justify in the current era of cost containment. However, due to the potential lethality of proarrhythmia, particularly in patients with structural heart disease, pre-drug assessment is prudent.
Collapse
Affiliation(s)
- J A Reiffel
- Department of Medicine, Columbia University College of Physicians & Surgeons, New York, New York
| | | |
Collapse
|
14
|
Abstract
In any discussion of lipids and heart disease it is beneficial from the outset to recognise that at least three different pathological processes may be involved. The first of these is atherosclerosis which involves the deposition of "fat" in the coronary vessels, another is thrombogenesis which describes the formation of blood clots in the coronary vessels, and the third is arrhythmia which refers to disorders in the beating of the heart which may become sufficiently serious to cause sudden cardiac death (SCD). Also it is this disturbance in the rhythmic beating of the heart which is responsible for much of the mortality from 'heart attacks' which occur 'outside-of-hospital' in societies like U.S.A., U.K. and Australia. It is this latter condition of cardiac arrhythmia which is the major concern of this review. Because it is often difficult to differentiate the role of lipids in 'heart disease' in man, it has frequently been assumed that all dietary fatty acids have similar effects on the different processes involved, and many unwarranted generalisations have been made which have led to conflicts of opinion amongst physicians and confusion in the lay public. From the animal studies discussed in this review, it is apparent that dietary fatty acids have an important role to play in determining the vulnerability of the myocardium to develop serious ventricular fibrillation (VF) and potentially lethal cardiac arrhythmia. In general, diets rich in saturated fatty acids promote a state of myocardial vulnerability, whilst diets rich in PUFA significantly diminish the probability of developing lethal disorders in cardiac rhythm when the heart is placed under pharmacological (or emotional) stress, or deprived of sufficient blood flow and supply of oxygen. Very recent experiments with the monounsaturated fatty acid (MUFA) oleic acid clearly demonstrate that, at least in rats subjected to ligation of their coronary artery, this acid is not 'neutral' as has been suggested by some for its role in atherosclerosis, but in fact is indistinguishable from saturated fatty acids in its effect in promoting arrhythmia during either regional ischaemia or reperfusion arrhythmia in this animal model of SCD.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- J S Charnock
- Cardiac Research Unit, Glenthorne Laboratory, CSIRO, Australia
| |
Collapse
|
15
|
Camm AJ, Julian D, Janse G, Munoz A, Schwartz P, Simon P, Frangin G. The European Myocardial Infarct Amiodarone Trial (EMIAT). EMIAT Investigators. Am J Cardiol 1993; 72:95F-98F. [PMID: 8237837 DOI: 10.1016/0002-9149(93)90970-n] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The objective of the European Myocardial Infarct Amiodarone Trial (EMIAT) is to assess the efficacy of amiodarone on mortality of patients with depressed left ventricular (LV) function following myocardial infarction (MI). The rationale for the trial is as follows: patients with poor LV function after acute MI have a high sudden cardiac death (SCD) mortality; amiodarone is a successful prophylactic therapy against SCD in patients with ventricular arrhythmias; a number of small studies (Canadian Amiodarone Myocardial Infarction Arrhythmia Trial [CAMIAT] pilot study, Basel Antiarrhythmic Study & Infarct Survival [BASIS], and the Polish Amiodarone Trial [PAT]) of prophylactic amiodarone post AMI have shown a beneficial response attributable to amiodarone. Patients are enrolled between 5 and 21 days after acute MI if LV ejection fraction (assessed by multiple-gated image acquisition nuclear angiography) is < or = 40%. The study group is stratified according to ejection fraction (stratum 1, 31-40%; stratum 2, < 31%). Amiodarone or placebo treatment (blind, randomized) is initiated prior to the discharge of the patient from the hospital and each patient is followed up for the duration of the study, at least 1 year. Recruitment began on November 30, 1990, and will continue for 4 years; > 700 patients are enrolled from > 60 centers (13 countries). The total study mortality (10% at 500 days) and the differential mortality of both strata are as anticipated. Side effects have been infrequent and very few patients have been withdrawn from the study. Trial conclusion is forecast for October 1995.
Collapse
Affiliation(s)
- A J Camm
- Department of Cardiological Sciences, St. George's Hospital Medical School, London, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
16
|
Reiffel JA, Correia J. Evolutionary paths in arrhythmia management: influences of substrate, studies, and seismology. Am Heart J 1993; 125:1207-11. [PMID: 7682034 DOI: 10.1016/0002-8703(93)90151-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
17
|
Affiliation(s)
- J K Gilman
- Electrophysiology Laboratory, University of Texas Medical School, Houston
| | | |
Collapse
|
18
|
Hansen O, Johansson BW, Gullberg B. Metabolic, hemodynamic, and electrocardiographic responses to increased circulating adrenaline: effects of pretreatment with class 1 antiarrhythmics. Angiology 1991; 42:990-1001. [PMID: 1763833 DOI: 10.1177/000331979104201209] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
In order to study the effects of treatment with class 1 antiarrhythmics on the metabolic, hemodynamic, and electrocardiographic responses to adrenaline, 12 healthy volunteers were infused on four occasions, after pretreatment with placebo, disopyramide, mexiletine, and flecainide, respectively, with adrenaline at a rate producing serum adrenaline concentrations comparable with those seen in acute myocardial infarction. After pretreatment with placebo adrenaline caused significant falls in serum potassium, serum magnesium, serum calcium, and serum phosphate and a significant increase in blood glucose. Adrenaline also caused a significant increase in heart rate and systolic blood pressure and a significant fall in diastolic blood pressure. On the electrocardiogram a significant prolongation of QTc duration and a flattening of the T-wave amplitude were seen. Pretreatment with disopyramide had no effect on the hemodynamic response to adrenaline but caused a significant prolongation of Qtc duration before the adrenaline infusion. Pretreatment with mexiletine was associated with a significantly greater fall in serum potassium during adrenaline infusion, and pretreatment with flecainide with a greater fall in serum magnesium, as compared with placebo pretreatment Flecainide also caused a significant prolongation of the QRS duration before adrenalin infusion, and after all the active pretreatments a prolongation of QRS duration was seen during adrenaline infusion. The metabolic and hemodynamic changes during adrenaline infusion may not only reduce the antiarrhythmic efficacy of antiarrhythmics but may also increase the risk of proarrhythmic effects in a clinical setting. These results may help to explain why treatment with antiarrhythmics seems to be without beneficial effect on mortality in post-myocardial infarction patients.
Collapse
Affiliation(s)
- O Hansen
- Section of Cardiology, Malmö General Hospital, Sweden
| | | | | |
Collapse
|
19
|
|
20
|
Kerin NZ, Frumin H, Faitel K, Aragon E, Rubenfire M. Survival of patients with nonsustained ventricular tachycardia and impaired left ventricular function treated with low-dose amiodarone. J Clin Pharmacol 1991; 31:1112-7. [PMID: 1753018 DOI: 10.1002/j.1552-4604.1991.tb03681.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- N Z Kerin
- Department of Medicine, Sinai Hospital, Detriot, MI 48235-2899
| | | | | | | | | |
Collapse
|
21
|
Podrid PJ, Fuchs TT. Left ventricular dysfunction and ventricular arrhythmias: reducing the risk of sudden death. J Clin Pharmacol 1991; 31:1096-104. [PMID: 1753015 DOI: 10.1002/j.1552-4604.1991.tb03678.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- P J Podrid
- Section of Cardiology, University Hospital, Boston, MA 02118
| | | |
Collapse
|
22
|
Abstract
Coronary artery disease is the leading cause of death in the United States. Approximately half of the deaths attributable to coronary artery disease are sudden cardiac deaths. A logical approach to prevention of sudden death is to identify those who are at risk and then to initiate effective therapy. Left ventricular dysfunction, frequent ventricular ectopic activity, nonsustained ventricular tachycardia, and late potentials have been identified as markers for increased risk of sudden cardiac death. The sensitivity and specificity of these risk factors vary, and the positive predictive power is less than satisfactory. The value of invasive electrophysiologic testing for risk stratification in the general postinfarction patient population remains unclear. In addition to these diagnostic difficulties, prevention of sudden death also has been limited by imperfect efficacy and potential lethal effects of the currently available antiarrhythmic agents. Automatic implantable defibrillators are effective for aborting sudden death; however, the potential for more general use of automatic defibrillators in asymptomatic but high-risk postinfarction patients has not been evaluated.
Collapse
MESH Headings
- Adult
- Arrhythmias, Cardiac/complications
- Arrhythmias, Cardiac/diagnosis
- Arrhythmias, Cardiac/therapy
- Clinical Protocols
- Coronary Disease/complications
- Coronary Disease/physiopathology
- Death, Sudden, Cardiac/epidemiology
- Death, Sudden, Cardiac/etiology
- Death, Sudden, Cardiac/prevention & control
- Electrocardiography
- Humans
- Myocardial Infarction/complications
- Myocardial Infarction/physiopathology
- Risk Factors
- Stroke Volume
- Ventricular Function, Left
Collapse
Affiliation(s)
- W K Shen
- Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, MN 55905
| | | |
Collapse
|
23
|
Schmidt G, Ulm K, Barthel P, Riemenschneider A, Linzmaier A, Goedel-Meinen L, Baedeker W, Blömer H. Evaluation of antiarrhythmic drug effects with simultaneous analysis of single ventricular premature contractions, couplets and salvos. J Am Coll Cardiol 1991; 18:138-43. [PMID: 1711061 DOI: 10.1016/s0735-1097(10)80230-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
To improve the clinical value of ambulatory Holter electrocardiographic (ECG) monitoring as a tool of antiarrhythmic therapy control, a new statistical model was developed. In a patient group at increased risk of sudden cardiac death, the spontaneous variability of ventricular arrhythmias was assessed, with simultaneous consideration of single ventricular premature complexes, couplets and salvos. The study included 100 patients who suffered from coronary heart disease or idiopathic dilated cardiomyopathy and for whom greater than 30 ventricular premature complexes/h and couplets had been demonstrated on the last Holter ECG before the study. Between 3 and 12 Holter recordings were made for each patient in a drug-free state; the mean follow-up period was 260 days (maximum 1,403). The mean hourly values of the ectopic events (EE) were assessed separately for ventricular premature complexes, couplets and salvos. The spontaneous variability (SV) was calculated for single ventricular premature complexes, couplets and salvos as SV = log (EEday 2 + 0.01/EEday 1 + 0.01) and linked in one, two and three dimensions. Compared with the consideration of only one type of arrhythmia (one-dimensional model), the simultaneous use of two or three types of arrhythmia (two- or three-dimensional model) resulted in considerably lower reduction and aggravation rates as sufficient proof of drug effects. With control intervals up to 1 week, the one-dimensional model yielded reduction rates for ventricular premature complexes, couplets and salvos of -63%, -90% and -95%, respectively. In contrast, with the three-dimensional model, the rates were -28%, -72% and -88%. The corresponding aggravation values were +370, +1,114% and +2,189% versus +38%, +256% and +747%.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- G Schmidt
- First Medical Clinic, Technical University of Munich, Germany
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781-8. [PMID: 1900101 DOI: 10.1056/nejm199103213241201] [Citation(s) in RCA: 1985] [Impact Index Per Article: 60.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
BACKGROUND AND METHODS In the Cardiac Arrhythmia Suppression Trial, designed to test the hypothesis that suppression of ventricular ectopy after a myocardial infarction reduces the incidence of sudden death, patients in whom ventricular ectopy could be suppressed with encainide, flecainide, or moricizine were randomly assigned to receive either active drug or placebo. The use of encainide and flecainide was discontinued because of excess mortality. We examined the mortality and morbidity after randomization to encainide or flecainide or their respective placebo. RESULTS Of 1498 patients, 857 were assigned to receive encainide or its placebo (432 to active drug and 425 to placebo) and 641 were assigned to receive flecainide or its placebo (323 to active drug and 318 to placebo). After a mean follow-up of 10 months, 89 patients had died: 59 of arrhythmia (43 receiving drug vs. 16 receiving placebo; P = 0.0004), 22 of nonarrhythmic cardiac causes (17 receiving drug vs. 5 receiving placebo; P = 0.01), and 8 of noncardiac causes (3 receiving drug vs. 5 receiving placebo). Almost all cardiac deaths not due to arrhythmia were attributed to acute myocardial infarction with shock (11 patients receiving drug and 3 receiving placebo) or to chronic congestive heart failure (4 receiving drug and 2 receiving placebo). There were no differences between the patients receiving active drug and those receiving placebo in the incidence of nonlethal disqualifying ventricular tachycardia, proarrhythmia, syncope, need for a permanent pacemaker, congestive heart failure, recurrent myocardial infarction, angina, or need for coronary-artery bypass grafting or angioplasty. CONCLUSIONS There was an excess of deaths due to arrhythmia and deaths due to shock after acute recurrent myocardial infarction in patients treated with encainide or flecainide. Nonlethal events, however, were equally distributed between the active-drug and placebo groups. The mechanisms underlying the excess mortality during treatment with encainide or flecainide remain unknown.
Collapse
Affiliation(s)
- D S Echt
- CAST Coordinating Center, Seattle, WA 98105
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Arrhythmia suppression in postmyocardial infarction patients with special notation to cardiac arrhythmia suppression trial. Prog Cardiovasc Dis 1991; 33:213-8. [PMID: 1994455 DOI: 10.1016/0033-0620(91)90026-i] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
26
|
Keung EC. Antiarrhythmic treatment and myocardial infarction. J Am Coll Cardiol 1990; 16:1719-21. [PMID: 2254559 DOI: 10.1016/0735-1097(90)90325-j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
27
|
Affiliation(s)
- P J Podrid
- Section of Cardiology, Boston University Medical School, Massachusetts
| |
Collapse
|
28
|
Anderson JL. Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug therapy after the cardiac arrhythmia suppression trial. J Clin Pharmacol 1990; 30:981-9. [PMID: 2122984 DOI: 10.1002/j.1552-4604.1990.tb03582.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The Cardiac Arrhythmia Suppression Trial (CAST) has led to serious reconsideration of both the benefit-risk ratio of antiarrhythmic drug therapy and the appropriate therapeutic approach to various cardiac arrhythmias. Class IC drugs, such as encainide and flecainide, should not be used to treat asymptomatic postinfarction arrhythmias. Furthermore, because the CAST raises serious questions about the concept of treating asymptomatic but "potentially malignant" (prognostically important) arrhythmias guided by ambulatory monitoring, the prophylactic use of any of the antiarrhythmic agents (except beta blockers) must be considered inappropriate and potentially harmful until otherwise established by specific clinical trials. For prophylaxis of malignant ventricular arrhythmias (sustained ventricular tachycardia or ventricular fibrillation), treatment may still begin with standard agents in classes IA, IB, or both, preferably guided by electrophysiologic testing alone or in combination with noninvasive testing. Class IC therapy may be most useful in those patients in this group who do not have such high-risk characteristics for proarrhythmia as a history of multiple myocardial infarctions (MIs), congestive heart failure, or low ejection fraction. Amiodarone is moderately effective for treating these arrhythmias but is reserved as second- or third-line therapy because of its potential organ toxicity. Sotalol, a beta blocker with class III activity, is often effective and relatively well tolerated in these patients and may become a preferred drug when approved. For symptomatic but nonmalignant ventricular arrhythmias, a more conservative approach is more appropriate than in the past, with therapy reversed for those with debilitating symptoms. An initial trial of beta blockade is often appropriate before class I agents are considered.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- J L Anderson
- Division of Cardiology, University of Utah Medical School, Salt Lake City
| |
Collapse
|
29
|
Abstract
Myocardial salvage can be maximized by the early institution of thrombolytic therapy and aspirin. Certain patients may benefit from the administration of intravenous heparin, beta blockers, or nitroglycerin. The routine use of percutaneous transluminal coronary angioplasty (PTCA) or calcium-channel blockers does not appear to be warranted. Recurrent myocardial ischemia should be vigorously treated with medical therapy and there may be value in cardiac catheterization, followed by PTCA or bypass surgery, depending upon the extent of myocardium at risk and the underlying coronary anatomy. Long-term morbidity and mortality may be reduced by instituting aspirin and beta blockers as well as by modifying risk factors. There is no evidence for the long-term benefit from any calcium-channel blocker. Oral anticoagulation may be warranted in those patients with a mural thrombus, congestive heart failure, or atrial fibrillation. ACE inhibitors may be of value in the presence of left ventricular dysfunction and certainly in the presence of symptomatic congestive heart failure. Antiarrhythmic therapy is generally indicated only for symptomatic or life-threatening arrhythmias. Residual myocardial ischemia should be sought by exercise testing, and those patients with poor exercise tolerance generally warrant cardiac catheterization in consideration for revascularization.
Collapse
Affiliation(s)
- D Massel
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada
| | | | | |
Collapse
|
30
|
Aronow WS, Mercando AD, Epstein S, Kronzon I. Effect of quinidine or procainamide versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in elderly patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1990; 66:423-8. [PMID: 2386118 DOI: 10.1016/0002-9149(90)90697-y] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
A prospective study correlated the effect of quinidine or procainamide versus no antiarrhythmic drug on sudden cardiac death, total cardiac death and total death in 406 elderly patients with heart disease and asymptomatic complex ventricular arrhythmias detected by 24-hour ambulatory electrocardiograms. Of 397 patients treated with quinidine, 184 (46%) developed adverse effects during the first 2 weeks of therapy and were given no further antiarrhythmic therapy. Of 9 patients treated with procainamide, 2 (22%) developed adverse effects during the first 2 weeks of therapy and were given no further antiarrhythmic therapy. Adverse effects developed during long-term therapy in 6 patients (2%) receiving quinidine and in 3 patients (33%) receiving procainamide. Mean follow-up was 24 +/- 15 months in both groups. Sudden cardiac death, total cardiac death and total death occurred in 21, 43 and 65% of patients receiving quinidine or procainamide, respectively, and in 23, 44 and 63% of patients receiving no antiarrhythmic drug, respectively (difference not significant). Survival by Kaplan-Meier analysis showed no significant difference between the 2 groups for sudden cardiac death, total cardiac death or total death through 4 years. Patients with abnormal left ventricular ejection fraction had a 3.4 times higher incidence of sudden cardiac death, a 2.4 times higher incidence of total cardiac death and a 1.4 times higher incidence of total death than patients with normal left ventricular ejection fraction. These data showed no significant difference in sudden cardiac death, total cardiac death or total death between patients treated with quinidine or procainamide or with no antiarrhythmic therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- W S Aronow
- Hebrew Hospital for Chronic Sick, Bronx, New York 10475
| | | | | | | |
Collapse
|
31
|
Anderson JL. Should complex ventricular arrhythmias in patients with congestive heart failure be treated? A protagonist's viewpoint. Am J Cardiol 1990; 66:447-50. [PMID: 2201180 DOI: 10.1016/0002-9149(90)90703-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- J L Anderson
- LDS Hospital, Cardiology, Salt Lake City, Utah 84143
| |
Collapse
|
32
|
Morganroth J, Bigger JT. Pharmacologic management of ventricular arrhythmias after the cardiac arrhythmia suppression trial. Am J Cardiol 1990; 65:1497-503. [PMID: 2091621 DOI: 10.1016/0002-9149(90)91362-a] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- J Morganroth
- Center of Excellence for Cardiovascular Studies, Graduate Health System, Philadelphia, Pennsylvania
| | | |
Collapse
|
33
|
Affiliation(s)
- J P DiMarco
- Department of Medicine, University of Virginia School of Medicine, Charlottesville
| | | |
Collapse
|
34
|
Latini R, Maggioni AP, Cavalli A. Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status. Clin Pharmacokinet 1990; 18:91-103. [PMID: 2180615 DOI: 10.2165/00003088-199018020-00001] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- R Latini
- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | | | | |
Collapse
|
35
|
Anderson JL. Clinical implications of new studies in the treatment of benign, potentially malignant and malignant ventricular arrhythmias. Am J Cardiol 1990; 65:36B-42B. [PMID: 2105050 DOI: 10.1016/0002-9149(90)91289-i] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
For purposes of clinical management, ventricular arrhythmias have been divided into risk categories of benign, prognostically important (potentially malignant) and malignant. Benign arrhythmias occur in the setting of structurally normal hearts and do not require therapy unless associated with debilitating symptoms. Malignant arrhythmias such as sustained ventricular tachycardia or fibrillation deserve aggressive therapy to prevent recurrence. Arrhythmias occurring in the presence of organic heart disease (often ischemic disease) are frequently asymptomatic but prognostically important as a risk factor for sudden death or cardiac arrest. The common empiric practice to treat such arrhythmias (by about 40 to 50% of cardiologists in the United States) needs to be reassessed in the face of the Cardiac Arrhythmia Suppression Trial. For malignant arrhythmias, class IA agents (procainamide and quinidine) continue to be the standard of treatment, and class IB agents (e.g., mexiletine) may be used as alternative or additive therapy. Class IC agents are used as second-line therapy, especially in the setting of ischemic heart disease. Class III therapy with amiodarone is reserved for refractory patients because of potential toxicity. Sotalol, a new class II-III agent, may become a first-line drug. For prognostically important arrhythmias, beta blockers remain the agents of choice, class IC agents are contraindicated, and class IA or IB drugs, or both, should be used conservatively (i.e., only for symptomatic arrhythmias). For symptomatic but benign arrhythmias requiring treatment, beta blockers are safe although not always effective. Class IA, IB and IC agents may then be considered. In these patients, the proarrhythmic potential of quinidine and class IC agents remains a concern.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- J L Anderson
- University of Utah School of Medicine, Salt Lake City
| |
Collapse
|
36
|
Abstract
Whereas much has been learned of the mechanisms and pathophysiology of cardiac arrhythmias, treatment remains controversial and is largely empiric. Cardiac arrhythmias range in severity from innocuous to fatal; antiarrhythmic agents offer differing degrees of efficacy, inefficacy or toxicity. For an arrhythmia that needs treatment, there is no reliable or easy method for selecting the most appropriate antiarrhythmic drug. Antiarrhythmic treatment is justified for arrhythmias that are symptomatic or hemodynamically significant, the risk of lethality dictating the degree of drug toxicity that might be tolerated. The treatment of prognostically important arrhythmias is indicated if their suppression is rewarded by an improved prognosis. However, these arrhythmias are often merely indicators of a bad prognosis rather than the cause of death. Assessment of the risk-benefit ratio of antiarrhythmic treatment principally depends on the perceived risk and symptomatology of the arrhythmia and the efficacy and toxicity of the antiarrhythmic drug. Beta-adrenoceptor blocking drugs offer optimal risk-benefits for the prevention of ventricular fibrillation (infarct survivors and long QT syndrome); disopyramide and the class IC agents offer acceptable risk-benefit ratios for the treatment of ventricular tachycardia, whereas no antiarrhythmic drug offers an acceptable risk-benefit for the suppression of asymptomatic "cosmetic" atrial or ventricular ectopic beats.
Collapse
Affiliation(s)
- R W Campbell
- Academic Department of Cardiology, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom
| | | |
Collapse
|
37
|
Affiliation(s)
- P J Podrid
- Section of Cardiology, Boston University, Massachusetts 02118-2393
| | | |
Collapse
|
38
|
Affiliation(s)
- B Surawicz
- Krannert Institute of Cardiology, Department of Medicine, Indiana University School of Medicine, Indianapolis 46202
| |
Collapse
|
39
|
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-12. [PMID: 2473403 DOI: 10.1056/nejm198908103210629] [Citation(s) in RCA: 2161] [Impact Index Per Article: 61.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The occurrence of ventricular premature depolarizations in survivors of myocardial infarction is a risk factor for subsequent sudden death, but whether antiarrhythmic therapy reduces the risk is not known. The Cardiac Arrhythmia Suppression Trial (CAST) is evaluating the effect of antiarrhythmic therapy (encainide, flecainide, or moricizine) in patients with asymptomatic or mildly symptomatic ventricular arrhythmia (six or more ventricular premature beats per hour) after myocardial infarction. As of March 30, 1989, 2309 patients had been recruited for the initial drug-titration phase of the study: 1727 (75 percent) had initial suppression of their arrhythmia (as assessed by Holter recording) through the use of one of the three study drugs and had been randomly assigned to receive active drug or placebo. During an average of 10 months of follow-up, the patients treated with active drug had a higher rate of death from arrhythmia than the patients assigned to placebo. Encainide and flecainide accounted for the excess of deaths from arrhythmia and nonfatal cardiac arrests (33 of 730 patients taking encainide or flecainide [4.5 percent]; 9 of 725 taking placebo [1.2 percent]; relative risk, 3.6; 95 percent confidence interval, 1.7 to 8.5). They also accounted for the higher total mortality (56 of 730 [7.7 percent] and 22 of 725 [3.0 percent], respectively; relative risk, 2.5; 95 percent confidence interval, 1.6 to 4.5). Because of these results, the part of the trial involving encainide and flecainide has been discontinued. We conclude that neither encainide nor flecainide should be used in the treatment of patients with asymptomatic or minimally symptomatic ventricular arrhythmia after myocardial infarction, even though these drugs may be effective initially in suppressing ventricular arrhythmia. Whether these results apply to other patients who might be candidates for antiarrhythmic therapy is unknown.
Collapse
|
40
|
Abstract
Sudden death claims an estimated 350,000 lives per year in the United States. When death occurs within 1 hour of the onset of symptoms, 90% are the result of ventricular tachyarrhythmias. The majority of victims are middle-aged men with coronary artery disease, but in approximately 25%, sudden death is the presenting manifestation of their problem. In some populations, the detection of premature ventricular complexes (PVCs) by ambulatory monitoring is predictive of an increased risk of sudden death. However, the arrhythmia that best predicts this risk is unclear, and ambient arrhythmias are only a modest marker of this risk. Therapy to suppress asymptomatic PVCs has not been shown to be effective in preventing sudden death, and in some cases, lethal arrhythmias can be prevented without significant effects on ambient arrhythmias. Other risk markers such as depressed left ventricular function and the presence of low-amplitude, long-duration, late potentials recorded on a signal averaged electrocardiogram are more powerful predictors of risk than are PVCs. These latter findings in particular support the presence of areas of slow electrical conduction (a requirement for reentrant mechanism arrhythmias) and suggest that an abnormal electrical environment or "substrate" is the most important factor in this problem. The management of patients at risk for sudden death is controversial. While postinfarct survivors with arrhythmias constitute a population at increased risk, the absolute risk is only about 5% in the first year and has not been shown to be improved by conventional antiarrhythmic drugs. Small study size, arrhythmia variability, ill-defined end points, and proarrhythmia may partially explain this apparent lack of efficacy. The prophylactic use of antiarrhythmic drugs other than beta-blockers to prevent sudden death in asymptomatic populations at risk is therefore of unproven benefit. By contrast, patients who have survived a life-threatening arrhythmia unrelated to an acute myocardial infarction have an approximately 30% risk of recurrence in the following year. In these patients, the use of ambulatory monitoring to guide therapy is limited by the high incidence of false-negative responses (lethal arrhythmia recurrence despite ambient arrhythmia suppression) and the lack of frequent spontaneous arrhythmias in many patients. In this patient population, electrophysiological testing can be used to prognosticate recurrence and gain insight into arrhythmia mechanism, stability, and hemodynamic tolerance. The technique is also useful in guiding both pharmacological and nonpharmacological therapy.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- M S Kremers
- University of Texas Southwestern Medical Center, Dallas
| | | | | |
Collapse
|
41
|
Affiliation(s)
- S Goldstein
- Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan 48202
| |
Collapse
|
42
|
Abstract
Primary ventricular fibrillation continues to be a major complication of acute myocardial infarction occurring in 5-9% of patients in the coronary care unit and in a higher percentage of pre-hospital admissions. Prophylactic anti-arrhythmic drugs can prevent primary ventricular fibrillation. Lidocaine has been used for this purpose and can be administered safely and effectively in most patients by following well-established programs based on pharmacokinetic and pharmacodynamic data. The in-hospital mortality for patients with primary ventricular fibrillation exceeds that of matched controls not having the arrhythmia, and many studies show a higher 1-, 3-, and 5-year mortality. Other studies have failed to confirm these long-term results and have produced controversy among cardiologists. I continue to recommend prophylactic antiarrhythmic drugs for all patients with acute infarction, especially in those undergoing early interventional therapy.
Collapse
Affiliation(s)
- D C Harrison
- University of Cincinnati Medical Center, Ohio 45267-0663
| |
Collapse
|
43
|
Kremers MS. The premise, promise, and perils of the prevention of lethal ventricular tachyarrhythmias. Am J Med Sci 1988; 296:202-20. [PMID: 3052060 DOI: 10.1097/00000441-198809000-00010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Sudden cardiac death caused by ventricular tachyarrhythmias claims about 360,000 lives a year in the United States. The premature ventricular complex (PVC) hypothesis has been the cornerstone for understanding this problem, but it is now recognized as an incomplete explanation for this catastrophy. The recognition of the importance of structural heart disease in this process has led to the development of the Substrate Hypothesis as an alternative explanation. In this construct, PVCs may trigger lethal arrhythmias but only if an abnormal electrophysiologic substrate is present. This hypothesis more completely describes the pathophysiology of the process, provides the basis for understanding the value and limitations of the techniques used for risk assessment and management, and helps clarify the potential endpoints and potential adverse effects of therapy to prevent arrhythmias. Since no single diagnostic technique is ideal and no therapeutic modality is universally effective, an approach to the management of this problem must be multidimensional and based on a firm understanding of the actual risk of a life threatening arrhythmia, the potential but unproven benefits and uncertain endpoints of drug therapy, the cost, and the potential for arrhythmia exacerbation or significant side effect.
Collapse
Affiliation(s)
- M S Kremers
- Department of Medicine, University of Texas Health Science Center, Dallas 75235-9034
| |
Collapse
|
44
|
Sager PT, Batsford WP. Ventricular Arrhythmias: Medical Therapy, Device Treatment, and Indications for Electrophysiologic Study. Cardiol Clin 1988. [DOI: 10.1016/s0733-8651(18)30500-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
45
|
Gottlieb SH, Ouyang P, Gottlieb SO. Death after acute myocardial infarction: interrelation between left ventricular dysfunction, arrhythmias and ischemia. Am J Cardiol 1988; 61:7B-12B. [PMID: 3277365 DOI: 10.1016/0002-9149(88)91348-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Patients who survive an acute myocardial infarction face an increased risk of sudden death for approximately 6 months after hospital discharge; their prognosis is determined by the severity of their coronary arteriosclerosis and the degree of left ventricular dysfunction. Frequent ventricular premature complexes and evidence of ischemia either spontaneously or on treadmill are also markers for early morbidity and mortality in patients who are discharged from the hospital after acute myocardial infarction. The degree of left ventricular dysfunction is the strongest predictor of mortality; patients who have both left ventricular dysfunction, frequent premature ventricular beats and evidence of ischemia are at the highest risk of mortality after hospital discharge. It appears likely that all 3 of these risk factors interact and that therapy to reduce morbidity and mortality after myocardial infarction should aim at the amelioration of each of these risk factors. A model for the interaction of these risk factors is proposed and an approach to treatment for patients at high risk of mortality after hospital discharge after myocardial infarction is suggested.
Collapse
Affiliation(s)
- S H Gottlieb
- Department of Medicine, Francis Scott Key Medical Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21224
| | | | | |
Collapse
|
46
|
Gottlieb SO. Association between silent myocardial ischemia and prognosis: insensitivity of angina pectoris as a marker of coronary artery disease activity. Am J Cardiol 1987; 60:33J-38J. [PMID: 3321968 DOI: 10.1016/0002-9149(87)90681-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The clinical syndrome of angina pectoris was accurately described over 200 years ago by Sir William Heberden. However, in recent years, we have learned that many episodes of myocardial ischemia occur that are not accompanied by symptoms of angina pectoris. These silent ischemic episodes may be detected either during exercise testing, using electrocardiographic criteria that can be combined with scintigraphic studies evaluating myocardial blood flow (thallium perfusion studies) or left ventricular function (gated blood pool scans). In addition, continuous electrocardiographic (Holter) monitoring can be used for the detection of transient ST-segment changes; these changes on Holter monitoring have been correlated with abnormalities of myocardial perfusion and function, indicating that they represent true ischemic events. Studies have shown that patients with coronary artery disease who have evidence of ongoing ischemia, whether symptomatic or silent, have an increased risk for experiencing subsequent cardiac events than patients without evidence of ischemia. Many studies have demonstrated that ischemia during an exercise study after myocardial infarction identifies patients at high risk for recurrent cardiac events, whether or not the ischemia is associated with angina pectoris. Holter monitoring has allowed for the detection of ischemic events out of hospital in ambulatory patients. Studies in stable angina patients have shown that there are many asymptomatic episodes in this setting, which are often occurring at low heart rates during activities of everyday life, without an apparent significant increase in myocardial oxygen demands, and these episodes may even be precipitated by mental stress.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- S O Gottlieb
- Department of Medicine, Francis Scott Key Medical Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21224
| |
Collapse
|
47
|
Lehmann MH, Steinman RT. Preventing sudden cardiac death. Postgrad Med 1987; 82:36-9, 43-5. [PMID: 3671215 DOI: 10.1080/00325481.1987.11700052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The syndrome of sudden cardiac death, which claims the lives of hundreds of thousands of Americans each year, is usually caused by ventricular tachycardia or fibrillation. Electrophysiologic testing is now being used to prevent recurrence of this syndrome in successfully resuscitated persons. With this procedure, antiarrhythmic drugs are assessed in terms of their ability to prevent induction of sustained ventricular tachyarrhythmias, rather than their ability to merely suppress ventricular premature beats. In medically unresponsive patients, an automatic cardioverter-defibrillator can be implanted to provide maximal protection from sudden cardiac death caused by ventricular tachyarrhythmias.
Collapse
Affiliation(s)
- M H Lehmann
- Division of Cardiology, Harper Hospital, Detroit, MI 48201
| | | |
Collapse
|